Risperidone Administered During Asymptomatic Period of Adolescence Prevents the Emergence of Brain Structural Pathology and Behavioral Abnormalities in an Animal Model of Schizophrenia

作者: Y. Piontkewitz , M. Arad , I. Weiner

DOI: 10.1093/SCHBUL/SBQ040

关键词:

摘要: Schizophrenia is a disorder of neurodevelopmental origin manifested symptomatically after puberty. Structural neuroimaging studies show that neuroanatomical aberrations precede onset symptoms, raising question whether schizophrenia can be prevented. Early treatment with atypical antipsychotics may reduce the risk transition to psychosis, but it remains unknown abnormalities We have recently shown, using in vivo structural magnetic resonance imaging, antipsychotic clozapine during an asymptomatic period adolescence prevents emergence schizophrenia-like brain adult rats exposed prenatal immune challenge, parallel preventing behavioral abnormalities. Here we assessed preventive efficacy risperidone (RIS). Pregnant were injected on gestational day 15 viral mimic polyriboinosinic-polyribocytidylic acid (poly I:C) or saline. Their male offspring received daily RIS (0.045 1.2 mg/kg) vehicle injection peri-adolescence (postnatal days [PND] 34–47). changes and behavior at adulthood (from PND 90). Adult poly I:C–treated dams exhibited hallmark associated schizophrenia, enlarged lateral ventricles smaller hippocampus. Both these absent I:C peri-adolescence. This was paralleled by prevention abnormalities, attentional deficit, hypersensitivity amphetamine offspring. conclude pharmacological intervention prevent pathology resulting from utero insult. Furthermore, highly selective 5HT2A receptor antagonists promising targets for psychosis prevention.

参考文章(99)
Monsheel S.K Sodhi, Elaine Sanders-Bush, Serotonin and brain development. International Review of Neurobiology. ,vol. 59, pp. 111- 174 ,(2004) , 10.1016/S0074-7742(04)59006-2
Cheng Lee, Thomas H McGlashan, Scott W Woods, Prevention of schizophrenia: can it be achieved? CNS Drugs. ,vol. 19, pp. 193- 206 ,(2005) , 10.2165/00023210-200519030-00002
Olivier Guillin, Anissa Abi‐Dargham, Marc Laruelle, Neurobiology of dopamine in schizophrenia. International Review of Neurobiology. ,vol. 78, pp. 1- 39 ,(2007) , 10.1016/S0074-7742(06)78001-1
Amy Wagner, Peter P. Roy-Byrne, Primary care perspectives on generalized anxiety disorder. The Journal of Clinical Psychiatry. ,vol. 65, pp. 20- 26 ,(2004)
PATRICK D. MCGORRY, EÓIN KILLACKEY, ALISON YUNG, Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry. ,vol. 7, pp. 148- 156 ,(2008) , 10.1002/J.2051-5545.2008.TB00182.X
Paul H. Patterson, Maternal Effects on Schizophrenia Risk Science. ,vol. 318, pp. 576- 577 ,(2007) , 10.1126/SCIENCE.1150196
Neil M Richtand, Robert K McNamara, None, Serotonin and dopamine interactions in psychosis prevention. Progress in Brain Research. ,vol. 172, pp. 141- 153 ,(2008) , 10.1016/S0079-6123(08)00907-2
F. Awouters, C. J. E. Niemegeers, A. A. H. P. Megens, K. H. L. Schellekens, T. F. Meert, P. A. J. Janssen, Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. Journal of Pharmacology and Experimental Therapeutics. ,vol. 244, pp. 685- 693 ,(1988)
Ou Bai, Jennifer Chlan-Fourney, Rudy Bowen, David Keegan, Xin-Min Li, Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs Journal of Neuroscience Research. ,vol. 71, pp. 127- 131 ,(2003) , 10.1002/JNR.10440
Gabriele Masi, Angela Cosenza, Maria Mucci, Paola Brovedani, A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. The Journal of Clinical Psychiatry. ,vol. 64, pp. 1039- 1047 ,(2003) , 10.4088/JCP.V64N0909